Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Brachytherapy. 2014 Nov-Dec;13(6):597-602. doi: 10.1016/j.brachy.2014.05.011. Epub 2014 Jun 7.

A case-control study of patients with squamous cell carcinoma of the oral cavity and oropharynx treated with pulsed-dose-rate brachytherapy.

Author information

  • 1Département de Radiothérapie, Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, France. Electronic address: ahaddad@toh.on.ca.
  • 2Département de Radiothérapie, Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, France.
  • 3Département de Radiothérapie, Centre Jean Perrin, Clermont-Ferrand, France.
  • 4Unité d'Activité et de Statistiques Médicales, Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, France.
  • 5Département de Physique, Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, France.

Abstract

PURPOSE:

Pulsed-dose-rate (PDR) brachytherapy is thought to mimic the radiobiological benefits of continuous low-dose-rate (cLDR) delivery but is safer for medical personnel. We set out to evaluate the outcomes of this technique in patients with head and neck squamous cell carcinoma.

METHODS AND MATERIALS:

A total of 36 consecutive patients treated with PDR brachytherapy were randomly matched to 72 cLDR controls according to T-stage, tumor site, and management strategy. Local recurrence and late complications were compared between the two groups.

RESULTS:

Baseline characteristics were similar in both groups. Oral cavity cancers predominated at 81%, and 89% had T1/T2 tumors. Seventy-five percent of patients underwent surgery before radiation treatment. Median followup was 59 and 30 months for cLDR and PDR patients, respectively. Three-year actuarial local recurrence-free survival was 97% and 94% for cLDR and PDR patients, respectively (p = 0.77). Three-year cumulative risk of Grade ≥2 complications was 45% and 32% for cLDR and PDR patients, respectively (p = 0.2). For cLDR, a dose rate exceeding 68 cGy/h resulted in more complications (RR 5.3, p < 0.05). Similarly, PDR patients receiving ≥75 cGy/pulse were at higher risk.

CONCLUSIONS:

PDR brachytherapy in head and neck squamous cell carcinoma yields comparable results to cLDR treatment. Dose rate was correlated with the risk of late complications, regardless of technique.

Crown Copyright © 2014. Published by Elsevier Inc. All rights reserved.

KEYWORDS:

Brachytherapy; Head and neck; PDR

PMID:
24913434
[PubMed - in process]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk